In this context, ketamine, an inhibitor of lysine acetyltransferase 5 (KAT5), reduces H3K27ac levels at GPX4 promoter regions to promote ferroptosis in breast cancer [108]. This evidence concerns the gene KAT5 and breast carcinoma.